用电子病历数据提前两年预测肝硬化,效果远超传统指标。
Early Prediction of Liver Cirrhosis Up to Two Years in Advance: A Machine Learning Study Benchmarking Against the FIB-4 and APRI Scores
- 用XGBoost模型分析病历数据,自动筛选关键特征并调参优化。
- 提前一年预测AUC达0.872,提前两年也达0.839,显著优于传统评分。
- 适合临床早筛系统集成,助力肝病预防与管理决策。
目的:利用常规电子健康记录(EHR)数据构建并评估机器学习(ML)模型,提前1年和2年预测新发肝硬化,并与FIB-4和APRI临床评分进行对比。方法:基于大型学术医疗系统的去标识化EHR数据开展回顾性队列研究。为1年和2年预测目标分别构建XGBoost模型,采用模型特异性特征选择与贝叶斯超参数调优以提升预测性能。在独立测试集上评估模型表现,并通过准确率、精确率、召回率、F1值、精确率-召回率曲线下面积(PR AUC)及受试者工作特征曲线下面积(AUC)与FIB-4和APRI进行比较。结果:最终建模人群分别为60,481例(1年预测)和47,322例(2年预测)。在两个预测窗口中,优化后的机器学习模型均显著优于FIB-4和APRI。XGBoost模型的AUC分别为0.872(1年)和0.839(2年),而FIB-4为0.756和0.723,APRI为0.798和0.761。在精确率-召回率指标上提升更明显,对应PR AUC分别为0.657和0.562(XGBoost),高于FIB-4的0.456和0.373,以及APRI的0.504和0.421。性能优势在更长预测窗口下仍保持,表明早期风险识别能力稳定。结论:基于常规EHR数据的机器学习模型可显著提升肝硬化的早期预测能力,实现更早更准的风险分层,具备嵌入临床工作流的潜力,支持肝硬化主动防控与管理。
原文摘要 · Abstract (English)
Objective: Develop and evaluate machine learning (ML) models for predicting incident liver cirrhosis (LC) one and two years prior to diagnosis using routinely collected electronic health record (EHR) data and benchmark their performance against the FIB-4 and APRI clinical scores. Methods: We conducted a retrospective cohort study using de-identified EHR data from a large academic health system. XGBoost models were developed for 1- and 2-year prediction horizons, with model-specific feature selection and Bayesian hyperparameter tuning applied to improve predictive performance. The model was then evaluated on held-out test sets, and its performance was compared with FIB-4 and APRI using accuracy, precision, recall, F1, area under the precision-recall curve (PR AUC), and area under the receiver operating characteristic curve (AUC). Results: Final modeling cohorts included 60,481 patients for the 1-year prediction and 47,322 for the 2-year prediction. Across both prediction windows, the tuned ML models consistently outperformed FIB-4 and APRI. The XGBoost models achieved AUCs of 0.872 and 0.839 for the 1- and 2-year predictions, respectively, compared with 0.756 and 0.723 for FIB-4 and 0.798 and 0.761 for APRI. Improvements were larger on the precision-recall metric, with PR AUCs of 0.657 and 0.562 for XGBoost compared with 0.456 and 0.373 for FIB-4 and 0.504 and 0.421 for APRI. Performance gains persisted with longer prediction horizons, indicating maintained early risk discrimination. Conclusions: Machine learning models leveraging routine EHR data substantially outperform the traditional FIB-4 and APRI scores for early prediction of liver cirrhosis. These models enable earlier and more accurate risk stratification and can be integrated into clinical workflows as automated decision-support tools to support proactive cirrhosis prevention and management.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。